Literature DB >> 8542247

Pharmacokinetic interaction of 5-fluorouracil and interferon alpha-2b with or without folinic acid.

J b1p6uller1, M Czejka.   

Abstract

The purpose of this study was to evaluate a potential pharmacokinetic (PK) interaction between fluorouracil (5-FU) and the biomodulating agent interferon alpha (IFN-alpha) in patients with metastatic colorectal carcinoma. 5-FU was applied as an intravenous bolus injection of 750 mg m-2 weekly and IFN-alpha 2b (IFN) 5 MU was injected 3 times weekly (TIW) subcutaneously. In the first study, 13 patients were treated by this schedule, 5-FU plasma levels were determined by HPLC on day (d) one as baseline before starting IFN; the analysis was repeated at the second or third cycle of 5-FU administration 1 hour after the last IFN injection respectively. In the second study, 10 patients additionally received folinic acid (FA) 200 mg m-2 as a short time infusion immediately before 5-FU, and a third analysis of FU kinetics was performed in order to compare the influence of a double modulation of IFN and FA to IFN alone. Combination of 5-FU and IFN resulted in a significant increase of the AUC of 5-FU (80%) and the fictive initial concentration (C0, 65%) obviously caused by a reduction of 5-FU clearance by 50%. However, when FA was added to this schedule, no significant changes of FU kinetics compared to 5-FU alone could be documented. Finally, in two pilot patients 5-FU 750 mg was given as a continuous infusion (CI) over 5 days and IFN 5 x 10(6) u was added daily from d2 to d5.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8542247     DOI: 10.1007/bf01571408

Source DB:  PubMed          Journal:  Med Oncol        ISSN: 1357-0560            Impact factor:   3.064


  36 in total

1.  Rapid and simple high-performance liquid chromatographic assay for 5'-fluorouracil in plasma for bioavailability studies.

Authors:  W Jäger; M J Czejka; J Schüller; U Fogl; E Czejka; H Lackner
Journal:  J Chromatogr       Date:  1990-11-16

2.  Recombinant interferon-gamma lacks activity against metastatic colorectal cancer but increases serum levels of CA 19-9.

Authors:  M J O'Connell; R A Ritts; C G Moertel; A J Schutt; S A Sherwin
Journal:  Cancer       Date:  1989-05-15       Impact factor: 6.860

3.  Interferon alpha-2a and 5-fluorouracil for advanced colorectal carcinoma. Assessment of activity and toxicity.

Authors:  N Kemeny; A Younes; K Seiter; D Kelsen; P Sammarco; L Adams; S Derby; P Murray; C Houston
Journal:  Cancer       Date:  1990-12-15       Impact factor: 6.860

Review 4.  Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review.

Authors:  S Wadler; E L Schwartz
Journal:  Cancer Res       Date:  1990-06-15       Impact factor: 12.701

5.  Phase II trial of alpha (human leukocyte) interferon administered daily in adenocarcinoma of the colon/rectum.

Authors:  R A Figlin; M Callaghan; G Sarna
Journal:  Cancer Treat Rep       Date:  1983-05

6.  Phase II trial of recombinant beta interferon in advanced colorectal cancer.

Authors:  P K Lillis; T D Brown; K Beougher; J Koeller; S G Marcus; D D Von Hoff
Journal:  Cancer Treat Rep       Date:  1987-10

7.  Clinical and immunological evaluation of 20 patients with advanced colorectal cancer treated with high dose recombinant leukocyte interferon-alpha A (rIFN alpha A).

Authors:  A M Eggermont; W Weimar; B Tank; A M Dekkers-Bijma; R L Marquet; J S Lameris; D L Westbroek; J Jeekel
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968

8.  Positive interactions between interferon and chemotherapy due to direct tumor action rather than effects on host drug-metabolizing enzymes.

Authors:  F R Balkwill; S Mowshowitz; S S Seilman; E M Moodie; D B Griffin; K H Fantes; C R Wolf
Journal:  Cancer Res       Date:  1984-11       Impact factor: 12.701

Review 9.  Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials.

Authors:  C H Köhne-Wömpner; H J Schmoll; A Harstrick; Y M Rustum
Journal:  Semin Oncol       Date:  1992-04       Impact factor: 4.929

Review 10.  Clinical pharmacology of 5-fluorouracil.

Authors:  R B Diasio; B E Harris
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.